Can a percussive breathing machine help meds reach scarred lungs?
NCT ID NCT05366387
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a device that delivers rapid puffs of air (intrapulmonary percussive ventilation) can help inhaled medication reach scarred lung areas in people with idiopathic pulmonary fibrosis (IPF). Nine participants inhaled a radioactive tracer with and without the device, and imaging measured how much reached fibrotic regions. The goal was to see if the technique is feasible and safe, not to treat the disease itself.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
intrapulmonary percussive ventilation device and 99mTc-DTPA aerosol
What this could lead to
If successful, this could show a way to deliver inhaled drugs more effectively to damaged lung areas in IPF, potentially improving future treatments.
What could go wrong
This is a very small, early feasibility study with only 9 participants, so results may not apply widely. It measures aerosol deposition, not actual treatment benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pulmonology Department, University Hospital, Tours
Tours, 37044, France